secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mineralys Therapeutics, Inc. (MLYS)
CIK:        0001933414
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001933414-25-000026
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Mineralys Therapeutics reports positive Phase 2 Advance-HTN trial results for lorundrostat in hypertension
--------------------------------------------------------------------------------

- Lorundrostat 50 mg achieved a 7.9 mmHg placebo-adjusted reduction in 24-hour SBP at week 12 (p=0.001).
- 41% of lorundrostat patients achieved 24-hour SBP <125 mmHg at week 4 vs 18% on placebo (p<0.001).
- Trial enrolled 53% Black and 40% female patients; safety showed low discontinuation and confirmed hyperkalemia rates of 2.1% and 3.2%.
- Company plans to provide additional Phase 3 Launch-HTN data at an upcoming medical conference.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1933414/000193341425000026/0001933414-25-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1933414/000193341425000026/mlys-20250329.htm
  HTML page:      https://secwatch.observer/filing/0001933414-25-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer